Press releases
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
- Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
- Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
- Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
- Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
More ▼
Key statistics
On Friday, ACADIA Pharmaceuticals Inc (ACAD*:MEX) closed at 509.00, 0.00% below its 52-week high of 509.00, set on Jul 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 509.00 |
---|---|
High | 509.00 |
Low | 509.00 |
Bid | 296.70 |
Offer | 296.70 |
Previous close | 291.12 |
Average volume | 0.00 |
---|---|
Shares outstanding | 164.77m |
Free float | 163.89m |
P/E (TTM) | -- |
Market cap | 2.81bn USD |
EPS (TTM) | -0.3774 USD |
Data delayed at least 20 minutes, as of Jul 14 2023 12:30 BST.
More ▼